Tate James Perque, PA-C

Tate Perque practices at CHRISTUS Highland Medical Center in Shreveport, Louisiana, part of CHRISTUS Health.

Tate Perque's NPI, 1003125055, was assigned on September 24, 2010. Tate Perque holds Louisiana license PA200387.

Tate Perque's primary practice is CHRISTUS Highland Medical Center, at 1453 E Bert Kouns Industrial Drive, Shreveport, LA 71105 in Caddo Parish. The practice phone is (318) 681-5000.

Tate Perque's primary practice is CHRISTUS Highland Medical Center in Shreveport, Louisiana, part of CHRISTUS Health. Tate Perque is also affiliated with Willis Knighton North. The medical group on file is CHRISTUS Trinity Clinic. Dmand AI also links Tate Perque to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tate Perque practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Tate Perque's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Tate Perque is licensed in Louisiana.

CMS data shows 144 Medicare services from Tate Perque across 8 procedure codes in 2024, for 86 Medicare patients. Medicare paid $9,489 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Tate Perque in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Tate Perque's median patient age at 68, with 31% women.

In 2024, Tate Perque wrote 274 Medicare Part D claims for 67 patients. 92% of them were for generic drugs. CMS names the drug for 197 of them, across 7 drugs with 11 or more claims each, at $919 in total drug cost.

Tate Perque accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 36 general payments to Tate Perque from 8 drug and device companies from 2024 to 2025. Consulting fees make up the largest share, 63% of the total. Terumo Cardiovascular Systems Corporation paid the most, $2,040.